To report a case of a perforated gastric ulcer associated with the use of injectable ketorolac tromethamine.
DATA SYNTHESIS:
A 77-year-old woman with no previous history of peptic ulcer disease developed a perforated gastric ulcer after four days of treatment with ketorolac. To date, six other cases of gastrointestinal (GI) perforation associated with the use of ketorolac have been reported to the manufacturer.
CONCLUSIONS:
Although ketorolac is an effective analgesic, it is a nonsteroidal antiinflammatory agent and thus has the propensity for causing GI ulceration. Caution should be used when administering this drug and patients should be monitored for GI adverse effects.
Methotrexate. In: McEvoyGKLitvakK, eds. American Hospital Formulary Service drug information 92. Bethesda, MD: American Society of Hospital Pharmacists, 1992: 577–83.
4.
KleimanRLAdairCGEphgraveKS. Stress ulcers: Current understanding of pathogenesis and prophylaxis. Drug Intell Clin Pharm1988; 22: 452–60.
5.
RothRHBennettRE. Nonsteroidal anti-inflammatory drug gastropathy. Arch Intern Med1987; 147: 2093–100.
6.
FlierJSUnderhillLH. Pathogenesis of peptic ulcer and implications for treatment. N Engl J Med1990; 322: 909–16.
7.
BrooksPM. Side-effects of non-steroidal anti-inflammatory drugs. Med J Aust1988; 148: 248–51.
